Quantitative Concept
Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval
Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth
Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments
Pharma stocks swerve as Trump hits pause on most tariffs
Market, Transplant Registry Unified Management Program, Pauses
Drug pricing watchdog ICER offers ways to increase obesity drug access
ICER, Obesity, Access, Wegovy, Policy, drug price
Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing
Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks
: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients
United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined
RFK Jr. promotes measles vaccine as Texas outbreak continues
Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas
Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots
Autoimmune, Autoimmune Diseases, Precision – temporal